Drug costs and nocebo risks: Navigating the Humira ‘biosimilar boom’ 1 year later

The first Humira biosimilar hit the U.S. market a little over a year ago. Since then, a total of nine biosimilars for Humira (adalimumab, AbbVie) have launched, including two with interchangeable status. However, despite promises of greater competition and reduced prices, it remains to be seen, now a full year from the launch of Amjevita (adalimumab-atto, Amgen) in January 2023, what impact these drugs will — or can — have on the U.S. pharmaceutical market and drug pricing system.

Read more: https://www.healio.com/news/rheumatology/20240208/drug-costs-and-nocebo-risks-navigating-the-humira-biosimilar-boom-1-year-later